Result of AGM
Updated : 14:30
20 May 2021
Venture Life Group plc
("Venture Life" or the "Group")
Result of AGM
Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that at its closed Annual General Meeting held earlier today, that all resolutions were duly passed.
For further information, please contact:
Venture Life Group PLC | +44 (0) 1344 578004 |
| |
Jerry Randall, Chief Executive Officer Andrew Waters, Chief Financial Officer |
| ||
Cenkos Securities plc (Nomad and Broker) |
+44 (0) 20 7397 8900 |
| |
Stephen Keys / Camilla Hume |
| ||
Russell Kerr / Michael Johnson (Sales) |
| ||
| |||
N+1 Singer (Joint Broker) | +44 (0) 20 7496 3000 | ||
Shaun Dobson / Carlo Spingardi (Corporate Finance) |
| ||
Jonathan Dighe (Sales) |
|
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands, these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies for consumer healthcare products, primarily medical devices.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.